$33.48
2.08% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

CRISPR Therapeutics AG Stock price

$34.19
-8.10 19.15% 1M
-11.52 25.20% 6M
-5.17 13.14% YTD
-30.84 47.42% 1Y
-35.32 50.81% 3Y
-5.32 13.46% 5Y
+20.10 142.65% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.05 3.17%
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

Key metrics

Market capitalization $2.93b
Enterprise Value $1.25b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 33.57
P/S ratio (TTM) P/S ratio 78.60
P/B ratio (TTM) P/B ratio 1.52
Revenue growth (TTM) Revenue growth -89.95%
Revenue (TTM) Revenue $37.31m
EBIT (operating result TTM) EBIT $-466.57m
Free Cash Flow (TTM) Free Cash Flow $-144.68m
Cash position $1.90b
EPS (TTM) EPS $-4.36
P/E forward negative
P/S forward 49.61
EV/Sales forward 21.19
Short interest 26.82%
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a CRISPR Therapeutics AG forecast:

17x Buy
57%
12x Hold
40%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
57%
Hold
40%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
37 37
90% 90%
100%
- Direct Costs 130 130
2% 2%
347%
-92 -92
138% 138%
-247%
- Selling and Administrative Expenses 54 54
5% 5%
144%
- Research and Development Expense 301 301
18% 18%
808%
-447 -447
149% 149%
-1,199%
- Depreciation and Amortization 19 19
3% 3%
52%
EBIT (Operating Income) EBIT -467 -467
134% 134%
-1,251%
Net Profit -366 -366
138% 138%
-982%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Negative
The Motley Fool
about 4 hours ago
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
Neutral
GlobeNewsWire
about 5 hours ago
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the firesi...
Negative
The Motley Fool
3 days ago
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website www.crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today